CoChat

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Mrak, Daniel, Tobudic, Selma, Koblischke, Maximilian, Graninger, Marianne, Radner, Helga, Sieghart, Daniela, Hofer, Philipp, Perkmann, Thomas, Haslacher, Helmuth, Thalhammer, Renate, Winkler, Stefan, Blüml, Stephan, Stiasny, Karin, Aberle, Judith H, Smolen, Josef S, Heinz, Leonhard X, Aletaha, Daniel, Bonelli, Michael · 2021 · Annals of the Rheumatic Diseases
Cited by 242

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Objectives Evidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-CoV-2 after immunisation. Methods Patients under RTX treatment (n=74) were vaccinated twice with either mRNA-1273 or BNT162b2. Antibodies were quantified using the Elecsys Anti-SARS-CoV-2 S immunoassay against the receptor-binding domain (RBD) of the spike protein and neutralisation tests. SARS-CoV-2-specific T-cell responses were quantified by IFN-γ enzyme-linked immunosorbent spot assays. Prepandemic healthy individuals (n=5), as well as healthy individuals (n=10) vaccinated with BNT162b2, served as controls. Results All healthy controls developed antibodies against the SARS-CoV-2 RBD of the spike protein, but only 39% of the patients under RTX treatment seroconverted. Antibodies against SARS-CoV-2 RBD significantly correlated with neutralising antibodies (τ=0.74, p<0.001). Patients without detectable CD19+ peripheral B cells (n=36) did not develop specific antibodies, except for one patient. Circulating B cells correlated with the levels of antibodies (τ=0.4, p<0.001). However, even patients with a low number of B cells (<1%) mounted detectable SARS-CoV-2-specific antibody responses. SARS-CoV-2-specific T cells were detected in 58% of the patients, independent of a humoral immune response. Conclusions The data suggest that vaccination can induce SARS-CoV-2-specific antibodies in RTX-treated patients, once peripheral B cells at least partially repopulate. Moreover, SARS-CoV-2-specific T cells that evolved in more than half of the vaccinated patients may exert protective effects independent of humoral immune responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2021-220781

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 242

Metadata

Authors
Mrak, D., Tobudic, S., Koblischke, M., Graninger, M., Radner, H., Sieghart, D., Hofer, P., Perkmann, T., Haslacher, H., Thalhammer, R., Winkler, S., Blüml, S., Stiasny, K., Aberle, J. H., Smolen, J. S., Heinz, L. X., Aletaha, D., & Bonelli, M.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2021-10
Volume
80
Issue
10
Pages
1345-1350
ISSN
0003-4967 (ISSN-L)
OpenAlex
W3184498267
Cited by
242
References
5
FWCI
16.58
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. https://app.cochat.ai/papers/10.1136/annrheumdis-2021-220781
The paper
Mrak, D., Tobudic, S., Koblischke, M., Graninger, M., Radner, H., Sieghart, D., Hofer, P., Perkmann, T., Haslacher, H., Thalhammer, R., Winkler, S., Blüml, S., Stiasny, K., Aberle, J. H., Smolen, J. S., Heinz, L. X., Aletaha, D., & Bonelli, M. (2021). SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2021-220781

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.